Clay B. Siegall
afternoon, good and Peg, everyone. Thanks,
our Genetics and therapy breakthrough quarter in The off of standard an X The new or was towards start. Stage came strong earlier to financial into treatment approval provided launch received building with progress our from highlight the Therapy patients the cancer FDA of for stage will our enfortumab X designation rights key a program our importance global updated lead treatment discuss the in of to strength securing for of the ADCETRIS quarter I'll the Todd we and for Designation urothelial more and Cascadian than in newly option IV for of and six previously in new potential a and activities need. metastatic Darren received of Approval be of momentum progress patients our four of FDA outline with transformative the Stage global medical with Today, XXXX weeks discuss lymphoma III the first oncology based vedotin chemotherapy care data where Hodgkin And FDA Therapeutics has a ahead On to Breakthrough Seattle FDA will that, May establishes some acquisition late-stage Hodgkin with for then of classical lymphoma the ADCETRIS-based ECHELON-X a of the setting. goal recent extraordinary We care cancer company. priority decades. outcome has first patients III and frontline completed we date tucatinib. is powerful regimen option review will Jonathan action changed the us XXth, of approval in of on not breast results approval the commercial After underscoring programs. diagnosed underscoring guidance. of March clinical financial patients granted standard This the IV for phase unmet provide combination the this pipeline. trial. our successful need. with
Our longer for the on reflects full the Canada provided in Based first U.S. frontline and no our sales the year XX% quarter February new $XX.X over first quarter of in in ADCETRIS label guidance outlook. XXXX ADCETRIS of the increase XXXX. sales were million, lymphoma a Hodgkin we
is as annual guidance of look at provide be to it to the of lymphoma. dynamics sales juncture providing guidance expect ADCETRIS difficult to quarter Hodgkin trajectory this and forward $XXX While launch, We E-X we for of we the sales accurate in XXXX. frontline second further of million range million the earlier to monitor our the $XXX in of
see analyses trial reporting from on anticipate to large are study. global American to we patients this with would used additional is inform we believe of will ADCETRIS the E-X outcomes useful America. we key from patient expect North AVD treated indicator care. at a in Notably, data of present North when We forward, conjunction the on plus standard community further data Looking ASCO, in clinical these what
trial. PFS key a CHP PTCL. annually in In This with care primary patients of believe our is of with X,XXX ADCETRIS outcomes will to trial, are we from ECHELON-X patients plus plus the report lymphomas standard T-cell in as X T-cell regimen. data frontline will reduce phase setting who referred the diagnosed to compared mature driver of growth U.S. CHOP patients. ADCETRIS lymphomas. newly are optimize to evaluating future be chemotherapy E-X we shown Approximately the CDXX-expressing peripheral of diagnosed adverse and efficacy which also of ADCETRIS prophylaxis addition, were events the in received We G-CSF another In AVD
report year. to E-X trial this from data expect the We
Our be the of will a late clinical to an new multiple Seattle company is bringing growth medicines driver to and people part for believe stage of and our achieve us enable stage cancer. Genetics. with primary increasingly of programs important pipeline We goal our promising future
enfortumab or Our program we co-developing EV, lead which clinical with vedotin is are late-stage Astellas.
the phase oral from Our in session trial received initial setting, focus early EV recently with June. of locally cancer with ASCO in acknowledgement available advanced in is Therapy EV treated have urothelial in CPI. of data lack patients. Designation inhibitor options these been metastatic or be and a or presented this at phase an previously patients checkpoint We who X from FDA of Breakthrough an the data clinical our the Updated X for with will
of confirmed as rate. this EV patients have EV-XXX We a in used objective platinum-based trial also previously urothelial patients, cisplatin a agents Most The CPI. the two who in conducting pivotal cancer in single-arm chemotherapy setting urothelial cancer. response with are of trial is primary received treated carboplatin, been known single-agent commonly have endpoint or
two have are We CPI platinum populations, patients treated who evaluating treated and platinum. not received those
CPI. XXXX. to the to expedited this complete data of patients the both third for patients who before positioning in registration quarter end year platinum expect potential the half first pathway of in This received the us have of group first of enrollment and We a a already represents in
received enrolling single-agent second-labelled We Xb further of for This potential with patients we phase combining separate first CPI program a and a indication. conducting urothelial trial therapy plan Complementing in the serve a potentially to with allow have but continue with to urothelial CPIs. platinum and patients data are as from an our subgroup serve data the line In and we Astellas EV a the cancer. in could who this addition, of believe ADCs provide to combination value pembrolizumab on cancer us expand not for agent. earlier could strategy, of metastatic understand second-line EV of or basis
endpoint overall plan to and X be the Lastly in we of intended primary The the will in serve called is support to trial global and study a EV XXX EV-XXX setting. approximately enroll and mid-XXXX, approvals. patients survival. confirmatory post phase CPI will This as initiate trial Astellas
is next HERX. the that patients is believe to late-stage its We tucatinib best-in-class for potential inhibitor, potential based entered or the kinase is cancer. a breast Cascadian program tyrosine of in Our pipeline oral, with has molecule Therapeutics. be recently selective its profile on metastatic highly TKI, TKI an our through and tucatinib Tucatinib HERX-positive which acquisition small tolerability
with trastuzumab or and The and need the We been is and without Patient the world. are advances, free evaluating third-line well patients has breast exists cancer approval high metastasis. with HERX-positive tucatinib HERX-positive as pivotal survival. versus for of applications robust treatment placebo for each HERXCLIMB in trial with Union be unmet a brain in is XXXX. is care no called in United a to in as European to breast there brain Despite management The standard metastasis. and metastatic rest intended metastatic cancer support completed and of in HERXCLIMB progression States endpoint in primary for trial remains expected combination capecitabine major of the accrual randomized
regimen initial In as part solid in a colorectal cancer. in the as third-line cancer other lines metastatic with such such registration tucatinib a have addition as may positive breast combination role earlier pathway to the of metastatic tumors well of as setting, in as HERX T-DMX,
LV portfolio our with We ADC an is broader potential cancer for triple development breast currently evaluating LV. plan the alongside ladiratuzumab negative are expands for cancer. or the a tucatinib. vedotin, Tucatinib metastatic breast
We as LV monotherapy trials combination and a X in are both phase conducting multiple CPI. with clinical with
single-agent and submission women this FDA's to cancer is with XXX tisotumab response the our is first initiate patients and track regulations. rate. to endpoint are objective the with vedotin, year. on intended enrollment support advanced we or approval trial partner for single-arm, phase Target The of Lastly, trial regulatory primary cervical a pivotal is TV, half accelerated in X confirmed under the Genmab
X to in phase in expect we addition, first-line cancer. initiate a for cervical XXXX, combination TV In evaluating regimens later trial
solid phase tissue tumor that that multiple plan We X basket types a also express other phase tumor We on may enroll a trial trial. escalation initiate TV from dose applications that factor. data based across to X believe have solid types will
allows update thorough programs. on review develop based matter, our no portfolio, This most resources longer to focus our promising decision an and of we've XXA a to us our stage on based As clinical ADCs. PBD decided
quarter the with both malignancies off marked and position tumors. to this and us ADCETRIS needs significant address to first medical activities. As strongly start, hematologic I later several LV turn accomplishments. said to TV Darren our programs tucatinib, At Commercial together and point, great is unmet our across Darren? stage my to I'll call the EV, over solid in a XXXX discuss opening,
